When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ENTA - EC OKs expanded 8-week regimen for AbbVie's hep C med Maviret
Enanta Pharmaceuticals Inc.
The European Commission approves an eight-week treatment regimen (formerly 12 weeks) for AbbVie's (NYSE:ABBV) Maviret (glecaprevir/pibrentasvir) for treatment-naïve, compensated cirrhotic, chronic hepatitis C (HCV) patients with genotype (GT) 3 infection.
More news on: AbbVie Inc., Enanta Pharmaceuticals, Inc., Healthcare stocks news,